Human growth hormone (GH) deficiency has an incidence of approximately 1/4,000 to 1/10,000 births. A significant proportion of cases must be familial because up to )0% of affected individuals have an affected parent or child. The cost of replacement therapy with GH derived by recombinant DNA techniques is significant and until recombinant DNA derived GH was available replacement with human GH was associated with risk for transmitting Creutzfeldt- Jakob disease due to viral contamination of GH isolated from human pituitaries. Arginine vasopressin (AVP) deficiency causes diabetes insipidus (DI) and about 1/50 human cases are familial. DI can be associated with significant morbidity and mortality and its treatment requires careful fluid, electrolyte and AVP replacement. In previous studies I have discovered that the molecular defect responsible for one form of familial GH deficiency is deletion of the GH genes. Treatment of this severe disorder is made difficult by the frequent occurrence of immunologic intolerance to exogenous GH. Preliminary linkage studies of familial DI suggest that an autosomal dominant form may be due to alterations of the AVP gene. My overall goals are to determine the molecular basis of various familial forms of GH or AVP deficiency and to determine the contribution of GH related genes to normal fetal growth. To achieve these goals I plan the following studies: 1) Determine the basic mechanism responsible for recurrent deletions of GH genes in humans; 2) derive a genetic linkage map of human chromosomes 17 and 20 that provide insight to the loci tightly linked to GH and AVP respectively; 3) determine the molecular basis of autosomal dominant, autosomal recessive and X-linked forms of GH deficiency; 4) determine the importance of selected GH related genes to fetal growth, and 5) determine the molecular basis of familial AVP deficiency. The genetic map distances found between various loci and the fetal expression of GH related genes are of general interest. Characterization of the basic defect(s) causing familial AVP or GH deficiency would have great importance in genetic counseling and understanding the pathogenesis of these disorders. Insight to their pathophysiology could, in turn, lead to possible alternative forms of therapy. Finally, mutations affecting the AVP and GH loci should have analogies to defects in other genetic disorders and should provide insight into the functional relationships between normal gene structure and function.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK035592-08
Application #
3233895
Study Section
Mammalian Genetics Study Section (MGN)
Project Start
1984-08-01
Project End
1994-04-30
Budget Start
1991-05-01
Budget End
1992-04-30
Support Year
8
Fiscal Year
1991
Total Cost
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Type
Schools of Medicine
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Poling, Justin S; Phillips 3rd, John A; Cogan, Joy D et al. (2011) Pharmacologic correction of dominant-negative GH1 deficiency causing mutations. Clin Transl Sci 4:175-9
Hamid, Rizwan; Phillips 3rd, John A; Holladay, Cindy et al. (2009) A molecular basis for variation in clinical severity of isolated growth hormone deficiency type II. J Clin Endocrinol Metab 94:4728-34
Mohamadi, Ali; Martari, Marco; Holladay, Cindy D et al. (2009) Mutation analysis of the muscarinic cholinergic receptor genes in isolated growth hormone deficiency type IB. J Clin Endocrinol Metab 94:2565-70
Solis, Amanda S; Peng, Rui; Crawford, J Barrett et al. (2008) Growth hormone deficiency and splicing fidelity: two serine/arginine-rich proteins, ASF/SF2 and SC35, act antagonistically. J Biol Chem 283:23619-26
Shariat, N; Holladay, C D; Cleary, R K et al. (2008) Isolated growth hormone deficiency type II caused by a point mutation that alters both splice site strength and splicing enhancer function. Clin Genet 74:539-45
Shariat, Nikki; Ryther, Robin C C; Phillips 3rd, John A et al. (2008) Rescue of pituitary function in a mouse model of isolated growth hormone deficiency type II by RNA interference. Endocrinology 149:580-6
Raskin, S; Petzl-Erler, M L; Phillips 3rd, J A et al. (2007) Cystic fibrosis gene variability in two southern Brazilian Amerindian populations: analysis of the deltaF508 mutation and the KM19 and XV2C haplotypes. Hum Biol 79:79-91
Hayashi, Yoshitaka; Kamijo, Takashi; Yamamoto, Michiyo et al. (2007) A case with isolated growth hormone deficiency caused by compound heterozygous mutations in GH-1: a novel missense mutation in the initiation codon and a 7.6kb deletion. Growth Horm IGF Res 17:249-53
Cogan, Joy D; Phillips 3rd, John A (2006) New methods in genetic diagnosis including prenatal diagnosis. Pediatr Endocrinol Rev 3 Suppl 3:424-33; discussion 434-6
Ryther, R C C; Flynt, A S; Phillips 3rd, J A et al. (2005) siRNA therapeutics: big potential from small RNAs. Gene Ther 12:5-11

Showing the most recent 10 out of 54 publications